Brief: Rigel Announces Publication Of Rezlidhia Mid-Stage Clinical Results In Blood Advances
02/02/2023 22:01
Feb 2 (Reuters) - Rigel Pharmaceuticals Inc RIGL.O :
* RIGEL ANNOUNCES PUBLICATION OF REZLIDHIA™ (OLUTASIDENIB)
PHASE 2
CLINICAL RESULTS IN BLOOD ADVANCES
* RIGEL PHARMACEUTICALS INC - REZLIDHIA INDUCED DURABLE
REMISSIONS
IN ADULT PATIENTS WITH MIDH1 R/R AML
Source text for Eikon: ID:nPn4RVHJ6a
Further company coverage: RIGL.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Rigel Pharmaceuticals
See all newsU.S. RESEARCH ROUNDUP- Berkshire Hathaway, Exxon Mobil, Honeywell Technologies
Rigel Pharmaceuticals Inc reports results for the quarter ended June 30 - Earnings Summary
Rigel Pharmaceuticals Q2 revenue rises on strong product demand
Brief: Rigel Pharmaceuticals - Appoints Alison L. Hannah As Executive Vice President And Chief Medical Officer Effective July 1, 2026 - SEC Filing
Brief: Rigel Announces Closing Of Licensing Agreement For Veppanu (Vepdegestrant)